Pharma / Biotech

Nerlynx Granted New Indication for Advanced or Metastatic HER2+ Breast Cancer

The FDA approved neratinib (Nerlynx, Puma) in combination with capecitabine for adults with advanced or metastatic HER2-positive breast cancer who have received two or more anti-HER2–based regimens in the metastatic setting.


Source link

Related posts

journal pharmacology; +784 new citations


SULFAMETHOXAZOLE AND TRIMETHOPRIM Tablet [Denton Pharma, Inc. DBA Northwind Pharmaceuticals]


‘NINJA’ Program Helps Prevent Pediatric AKI


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy